112 related articles for article (PubMed ID: 12829987)
21. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
[TBL] [Abstract][Full Text] [Related]
22. Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon.
Sakamoto N; Yoshimura M; Kimura T; Toyama K; Sekine-Osajima Y; Watanabe M; Muramatsu M
Biochem Biophys Res Commun; 2007 Jun; 357(2):467-73. PubMed ID: 17433261
[TBL] [Abstract][Full Text] [Related]
23. Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.
Murao K; Imachi H; Yu X; Cao WM; Nishiuchi T; Chen K; Li J; Ahmed RA; Wong NC; Ishida T
Gut; 2008 May; 57(5):664-71. PubMed ID: 17998316
[TBL] [Abstract][Full Text] [Related]
24. Nuclear factor-kappa B in the liver of patients with chronic hepatitis C: decreased RelA expression is associated with enhanced fibrosis progression.
Boya P; Larrea E; Sola I; Majano PL; Jiménez C; Civeira MP; Prieto J
Hepatology; 2001 Nov; 34(5):1041-8. PubMed ID: 11679977
[TBL] [Abstract][Full Text] [Related]
25. State of hepatitis C viral replication enhances activation of NF-kB- and AP-1-signaling induced by hepatitis B virus X.
Kanda T; Yokosuka O; Nagao K; Saisho H
Cancer Lett; 2006 Mar; 234(2):143-8. PubMed ID: 15885885
[TBL] [Abstract][Full Text] [Related]
26. Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation.
Fimia GM; Evangelisti C; Alonzi T; Romani M; Fratini F; Paonessa G; Ippolito G; Tripodi M; Piacentini M
J Virol; 2004 Dec; 78(23):12809-16. PubMed ID: 15542633
[TBL] [Abstract][Full Text] [Related]
27. Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption.
Carrière M; Rosenberg AR; Conti F; Chouzenoux S; Terris B; Sogni P; Soubrane O; Calmus Y; Podevin P
J Viral Hepat; 2006 Sep; 13(9):633-42. PubMed ID: 16907851
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of the interferon alpha response against hepatitis C virus replicons.
Guo JT; Sohn JA; Zhu Q; Seeger C
Virology; 2004 Jul; 325(1):71-81. PubMed ID: 15231387
[TBL] [Abstract][Full Text] [Related]
29. Morphine withdrawal enhances hepatitis C virus replicon expression.
Wang CQ; Li Y; Douglas SD; Wang X; Metzger DS; Zhang T; Ho WZ
Am J Pathol; 2005 Nov; 167(5):1333-40. PubMed ID: 16251417
[TBL] [Abstract][Full Text] [Related]
30. CD40 expression in HCV-associated chronic liver diseases.
Shiraki K; Sugimoto K; Okano H; Wagayama H; Fujikawa K; Yamanaka T; Ito T; Ohmori S; Sakai T; Takase K; Nakano T
Int J Mol Med; 2006 Oct; 18(4):559-63. PubMed ID: 16964404
[TBL] [Abstract][Full Text] [Related]
31. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
32. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
[TBL] [Abstract][Full Text] [Related]
33. Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents.
Nishimura G; Ikeda M; Mori K; Nakazawa T; Ariumi Y; Dansako H; Kato N
Antiviral Res; 2009 Apr; 82(1):42-50. PubMed ID: 19428594
[TBL] [Abstract][Full Text] [Related]
34. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.
Urbani S; Amadei B; Tola D; Pedrazzi G; Sacchelli L; Cavallo MC; Orlandini A; Missale G; Ferrari C
J Hepatol; 2008 Apr; 48(4):548-58. PubMed ID: 18280607
[TBL] [Abstract][Full Text] [Related]
35. Anti-hepatitis C virus activity of Acacia confusa extract via suppressing cyclooxygenase-2.
Lee JC; Chen WC; Wu SF; Tseng CK; Chiou CY; Chang FR; Hsu SH; Wu YC
Antiviral Res; 2011 Jan; 89(1):35-42. PubMed ID: 21075144
[TBL] [Abstract][Full Text] [Related]
36. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model.
Umehara T; Sudoh M; Yasui F; Matsuda C; Hayashi Y; Chayama K; Kohara M
Biochem Biophys Res Commun; 2006 Jul; 346(1):67-73. PubMed ID: 16750511
[TBL] [Abstract][Full Text] [Related]
37. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
Xu J; Liu S; Xu Y; Tien P; Gao G
Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
[TBL] [Abstract][Full Text] [Related]
38. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
Ikeda M; Abe K; Yamada M; Dansako H; Naka K; Kato N
Hepatology; 2006 Jul; 44(1):117-25. PubMed ID: 16799963
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways.
Alisi A; Ghidinelli M; Zerbini A; Missale G; Balsano C
J Hepatol; 2011 May; 54(5):956-63. PubMed ID: 21145809
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus replicons: potential role for drug development.
Bartenschlager R
Nat Rev Drug Discov; 2002 Nov; 1(11):911-6. PubMed ID: 12415250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
